Subscribe To
Lantheus: fast-growing radiotherapeutics specialist can benefit from lilly's point biopharma takeover
Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product <...
October 12, 2023, 4:35 pm
Lantheus: not quite ready to take the plunge
Radiopharmacy is expected to experience exponential growth over the next decade. Radiopharmaceutical-based therapies offer more targeted and specific ...
August 30, 2023, 8:20 am
Lantheus: pylarify and definity driving strong growth
Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The...
June 18, 2023, 3:54 am
Lantheus announces presentations featuring pylarify ai™ at the 2023 society for nuclear medicine and molecular imaging (snmmi) annual meeting
BEDFORD, Mass., June 12, 2023 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outc...
June 12, 2023, 12:30 pm
Lantheus: managing a winner
Lantheus Holdings reported a strong beat on their fourth-quarter and full-year 2021 earnings. pylarify ...
April 7, 2022, 1:29 pm